financial guidance
The company also said that its Diagnostics and Genomics revenues were down 1 percent during fiscal Q4, although its overall revenues were up slightly.
Natera Q3 Revenues Grow 64 Percent
Strong product sales, mainly from oncology tests, drove the company's revenue growth, prompting it to raise its full year guidance.
Quanterix Counting on Multi-Marker Approach as Differentiator in Crowded Alzheimer's Dx Field
Premium
The company expects its five-marker LucentAD Complete test to offer higher performance than single-marker assay and to secure higher reimbursement.
Exagen Q3 Revenues Decline 7 Percent
The firm said its Q3 revenues were negatively impacted by $1.2 million in one-time adjustments.
In the wake of suspending guidance to review the business in the first quarter of the year, QuidelOrtho has restructured and resumed offering a financial outlook.
Nov 7, 2024
Becton Dickinson Q4 Revenues Grow 7 Percent
Oct 30, 2024
Standard BioTools Q3 2024 Revenues Fall 5 Percent
Oct 24, 2024
Labcorp Q3 Revenues Rise 7 Percent
Oct 22, 2024
Oct 16, 2024
Abbott Q3 Diagnostics Revenues Down 2 Percent
Oct 15, 2024
CareDx Preliminary Q3 Revenues Rise 23 Percent
Aug 8, 2024